Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Fusion Antibodies (FAB) Share Price

Price 6.10p on 30-05-2025 at 18:50:06
Change -0.05p -0.81%
Buy 6.20p
Sell 6.00p
Buy / Sell FAB Shares
Last Trade: Buy 70,000.00 at 6.17p
Day's Volume: 1,096,831
Last Close: 6.10p
Open: 6.15p
ISIN: GB00BDQZGK16
Day's Range 6.10p - 6.40p
52wk Range: 2.90p - 10.50p
Market Capitalisation: £6m
VWAP: 6.305806p
Shares in Issue: 105m

Fusion Antibodies (FAB) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 70,000 6.17p Ordinary
16:22:48 - 30-May-25
Buy* 41,935 6.1599p Ordinary
16:21:29 - 30-May-25
Sell* 25,000 6.00p Ordinary
16:15:19 - 30-May-25
Sell* 40,000 6.0263p Ordinary
16:12:54 - 30-May-25
Buy* 2,469 6.44p Ordinary
16:06:18 - 30-May-25
Sell* 100,000 6.14p Ordinary
16:00:45 - 30-May-25
Sell* 40,000 6.0558p Ordinary
15:50:23 - 30-May-25
Sell* 10,000 6.14p Ordinary
15:27:26 - 30-May-25
Buy* 43,988 6.579p Ordinary
14:57:14 - 30-May-25
Buy* 48,500 6.576p Ordinary
14:31:12 - 30-May-25
See more Fusion Antibodies trades

Fusion Antibodies (FAB) Share Price History

Time period:
to
Date Open High Low Close Volume
30th May 2025 (Fri) 6.15 6.40 6.10 6.10 1,096,831
29th May 2025 (Thu) 6.55 6.55 6.15 6.15 192,912
28th May 2025 (Wed) 6.65 6.65 6.55 6.55 290,607
27th May 2025 (Tue) 6.70 6.70 6.40 6.65 846,155
26th May 2025 (Mon) 6.90 6.90 6.90 6.90 0
23rd May 2025 (Fri) 6.85 6.85 6.70 6.70 246,276
22nd May 2025 (Thu) 6.50 7.50 6.50 6.85 2,466,706
21st May 2025 (Wed) 6.65 6.65 6.45 6.45 419,023
20th May 2025 (Tue) 6.75 6.75 6.65 6.65 426,986
19th May 2025 (Mon) 6.75 6.75 6.75 6.75 132,450
16th May 2025 (Fri) 6.30 6.75 6.30 6.75 630,359
15th May 2025 (Thu) 6.10 6.30 6.10 6.30 535,696
14th May 2025 (Wed) 6.10 6.46 6.10 6.10 88,529
13th May 2025 (Tue) 6.10 6.10 6.10 6.10 105,380
12th May 2025 (Mon) 5.80 6.15 5.80 6.10 423,783
9th May 2025 (Fri) 5.95 5.95 5.80 5.80 230,351
8th May 2025 (Thu) 5.80 5.95 5.80 5.95 1,211,170
7th May 2025 (Wed) 6.10 5.95 5.80 5.80 1,876,187
6th May 2025 (Tue) 6.50 6.50 5.90 6.10 3,345,334
5th May 2025 (Mon) 6.685 6.685 6.685 6.685 0
2nd May 2025 (Fri) 6.50 6.55 6.50 6.55 312,476
1st May 2025 (Thu) 6.75 6.75 6.45 6.50 315,690
See more Fusion Antibodies price history

Fusion Antibodies (FAB) Regulatory News

Date Source Headline
22nd May 2025 2:33 pm RNS Update on U.S. Patent for OptiMAL®
8th May 2025 7:00 am RNS-R Investor presentation
7th May 2025 7:00 am RNS Issue of shares to non-executive directors
6th May 2025 10:53 am RNS Director/PDMR Shareholding
6th May 2025 10:38 am RNS Holding(s) in Company
6th May 2025 7:00 am RNS Trading update
30th Apr 2025 5:00 pm RNS Total Voting Rights
24th Apr 2025 7:00 am RNS Approval of grant funding
11th Apr 2025 10:40 am RNS Holding(s) in Company
10th Apr 2025 12:47 pm RNS Holding(s) in Company
See more Fusion Antibodies regulatory news

Fusion Antibodies (FAB) Share News

TRADING UPDATES: Poolbeg upsizes offer; Glenveagh backs outlook

22nd May 2025 22:51

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Fusion Antibodies receives approval of grant funding application

4th Dec 2024 12:18

(Alliance News) - Fusion Antibodies PLC on Wednesday announced the approval of a grant funding application to The Northern Ireland Precision Biomarkers & Therapeutics consortium, of which it is a member. Read More

Fusion Antibodies interim loss narrows as revenue more than doubles

19th Nov 2024 13:10

(Alliance News) - Fusion Antibodies PLC on Tuesday said its loss narrowed in the first half of its current financial year, as revenue more than doubled. Read More

IN BRIEF: Fusion Antibodies expects interim revenue to double

8th Oct 2024 13:58

Fusion Antibodies PLC - Belfast-based contract researcher that provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Expects revenue of around GBP1.2 million for the six months to September 30, more than doubling from GBP541,000 at the same time last year. Its gross margin is expected to be 29%, compared to negative 16% the year prior. Fusion Antibodies expands its collaboration agreement with the National Cancer Institute in the six-month period to include the company's humanisation of the NCI's existing camelid nanobodies, and secures a new contract for an antibody based therapeutic with an unnamed US-based biotechnology company. It is also contracted to develop a bespoke OptiPhage library for an unnamed client. The company remains on track with its strategic goals. Read More

UK shareholder meetings calendar - next 7 days

1st Oct 2024 15:33

Read More

See more Fusion Antibodies news
FTSE 100 Latest
Value8,772.38
Change55.93

Login to your account

Forgot Password?

Not Registered